Yahoo
KSE - Delayed Quote KRW

Daewoong Pharmaceutical Co., Ltd (069620.KS)

102,300.00 +1,200.00 (+1.19%)
As of 10:10:30 AM GMT+9. Market Open.
View in AlphaSpace Currency in KRW All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
1,635,214,573.30
1,570,891,005.32
1,422,683,296.38
1,375,328,744.87
1,280,091,851.01
Cost of Revenue
780,578,798.10
748,359,218.86
688,515,743.85
687,162,023.95
641,134,291.17
Gross Profit
854,635,775.20
822,531,786.46
734,167,552.53
688,166,720.92
638,957,559.84
Operating Expense
664,129,013
625,749,372
586,225,354
565,574,772
543,160,411
Operating Income
190,506,762.20
196,782,414.46
147,942,198.53
122,591,948.92
95,797,148.84
Net Non Operating Interest Income Expense
-11,179,672.65
-9,879,587.85
-1,893,559.71
-10,503,528.72
3,674,379.42
Pretax Income
179,560,063.37
191,833,139.35
56,550,480.23
121,999,263.70
38,329,656.95
Tax Provision
1,120,071.11
-1,075,779.71
33,203,971.73
1,996,359.48
-833,512.38
Net Income Common Stockholders
195,472,789.09
195,855,574.63
24,734,510.69
121,738,683.17
42,239,518.34
Basic EPS
16.99k
17.02k
2.15k
10.66k
3.82k
Diluted EPS
16.99k
17.02k
2.15k
10.66k
3.82k
Basic Average Shares
11,505.73
11,506.03
11,504.42
11,424.43
11,069.06
Diluted Average Shares
11,505.73
11,506.03
11,504.42
11,424.43
11,069.06
Total Operating Income as Reported
190,506,763.66
196,782,415.37
147,942,198.47
122,591,949.28
95,797,148.53
Rent Expense Supplemental
3,906,508
2,972,559
2,357,055
2,471,585
2,397,905
Total Expenses
1,444,707,811.10
1,374,108,590.86
1,274,741,097.85
1,252,736,795.95
1,184,294,702.17
Net Income from Continuing & Discontinued Operation
195,472,789.09
195,855,574.63
24,734,510.69
121,738,683.17
42,239,518.34
Normalized Income
198,892,599.87
215,324,458.91
63,077,731.25
127,209,000.38
49,753,748.22
Interest Income
3,458,895
2,595,903
5,092,808
3,099,375
4,127,645
Interest Expense
14,638,568
12,475,490
6,986,368
13,602,904
8,405,545
Net Interest Income
-11,179,672.65
-9,879,587.85
-1,893,559.71
-10,503,528.72
3,674,379.42
EBIT
194,198,631.37
204,308,629.35
63,536,848.23
135,602,167.70
46,735,201.95
EBITDA
261,784,193.37
255,381,078.35
112,515,244.23
179,399,019.70
86,429,865.95
Reconciled Cost of Revenue
780,578,798.10
748,359,218.86
688,515,743.85
687,162,023.95
641,134,291.17
Reconciled Depreciation
67,585,562
51,072,449
48,978,396
43,796,852
39,694,664
Net Income from Continuing Operation Net Minority Interest
195,472,789.09
195,855,574.63
24,734,510.69
121,738,683.17
42,239,518.34
Total Unusual Items Excluding Goodwill
-3,441,277
-25,616,953
-50,451,606
-5,561,321
-10,364,455
Total Unusual Items
-3,441,277
-25,616,953
-50,451,606
-5,561,321
-10,364,455
Normalized EBITDA
265,225,470.37
280,998,031.35
162,966,850.23
184,960,340.70
96,794,320.95
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-21,466.22
-6,148,068.72
-12,108,385.44
-91,003.79
-2,850,225.13
12/31/2022 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: